News

MSCAI recipients to be recognized during SCAI 2022 Scientific Sessions in Atlanta

New partnership will provide physician training to drive improved diversity in clinical trials Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary...

EXPAND TAVR II Pivotal Trial evaluating the Evolut™ TAVR platform in a new patient population

Commonly prescribed hypertension drugs may be harmful in combination with ibuprofen

May 9, 2022 — Through single-cell RNA sequencing, a research group has successfully illuminated the characteristics of Myeloid immune cells in coronary plaque, which causes acute coronary syndrome (this term includes conditions such as...

Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del., May 5, 2022 – High-level results from the DELIVER Phase III trial showed...

Sophia Antipolis – 30 April 2022: A method for delivering genetic material to the body is being tested as a way to repair damaged heart muscle after a heart attack. The ground-breaking research is presented today at Frontiers in...

May 2, 2022 — A new study suggests that reducing daily sedentary time can have a positive effect on the risk factors of lifestyle diseases already in three months. Spending just one hour less sitting daily and increasing light physical...

EXPAND TAVR II Pivotal Trial evaluating the Evolut™ TAVR platform in a new patient population

Treatment with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ resulted in patients with persistent atrial fibrillation experiencing an improved quality of life.